Pohang-si, South Korea

Eun-Jung Jang


Average Co-Inventor Count = 9.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Eun-Jung Jang: Innovator in Oligonucleotide Research

Introduction

Eun-Jung Jang is a prominent inventor based in Pohang-si, South Korea. She has made significant contributions to the field of oligonucleotide research, particularly in the development of aptamers and methods for preparing oligonucleotide derivatives. With a total of 2 patents, her work has implications for diagnosing and treating diseases associated with nucleolin.

Latest Patents

Eun-Jung Jang's latest patents include the following:

1. **Nucleolin specific aptamer and use thereof** - This patent focuses on improved G-rich oligonucleotide (GRO) aptamers that are specific to nucleolin. It outlines a method for preparing these aptamers and their potential use in diagnosing and/or treating nucleolin-associated diseases.

2. **Method of preparing 5'-amino-linker oligonucleotides derivatives and analogous 5'-labeled-linker oligonucleotides therefrom** - This patent describes a method for preparing amino linker oligonucleotides. It details the steps involved in introducing an amino linker with a protecting group into the 5' terminus of an oligonucleotide and subsequently removing the protecting group to achieve a high yield of amino linker oligonucleotides.

Career Highlights

Eun-Jung Jang has worked with notable organizations such as the Postech Academy-Industry Foundation and Posco. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.

Collaborations

Eun-Jung has collaborated with esteemed colleagues, including Jung-Hwan Lee and Hyun-Gu Kang. These partnerships have fostered innovation and enhanced the impact of her research.

Conclusion

Eun-Jung Jang is a distinguished inventor whose work in oligonucleotide research has the potential to revolutionize diagnostics and treatment options for nucleolin-associated diseases. Her contributions continue to shape the future of this important field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…